Formulation and Characterization of Sustained Release Floating Microballoons of Metformin Hydrochloride by Yadav, A & Jain, DK
Halder et al  
Trop J Pharm Res, August 2012;11 (4): 561 
Tropical Journal of Pharmaceutical Research August 2012; 11 (4): 561-568 
© Pharmacotherapy Group,  
Faculty of Pharmacy, University of Benin,  
Benin City, 300001 Nigeria.  
All rights reserved. 
 







Formulation and Characterization of Sustained 
Release Floating Microballoons of Metformin 
Hydrochloride 
 
Akash Yadav* and Dinesh Kumar Jain 
1Department of Pharmaceutics, College of Pharmacy, Indore Professional Studies (IPS) Academy, Knowledge 







Purpose: To formulate sustained release gastroretentive microballoons of metformin hydrochloride with 
the objective of improving its bioavailability. 
Methods: Microballoons of metformin hydrochloride were formulated by solvent evaporation and 
diffusion method using varying mixtures of hydroxypropyl methylcellulose (HPMC) and ethyl cellulose 
(EC) polymers. The balloons were characterized for particle size, surface morphology, incorporation 
efficiency, floating behavior and in vitro drug release.  
Results: The mean particle size of the formulated microballoons was in the range of 34.2 ± 4.7 to 95.7 ± 
2.2 µm. Incorporation efficiencies of over 83.8 ± 0.9 % were achieved for the optimized formulations. 
Most of the formulations were buoyant with maximum buoyancy of 81.4 ± 2.0 % for > 12 h, showing 
good floating behavior of microballoons. Release kinetic data showed best fit to the Higuchi model, 
indicating that diffusion was the predominant mechanism of drug release.  
Conclusion: Microballoons is a potential suitable delivery system for sustained release of metformin 
hydrochloride with improved bioavailability when compared with conventional dosage forms of the drug. 
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Oral administration is the most convenient 
and preferred route of drug delivery to the 
systemic circulation. Many attempts have 
been made to develop sustained release 
preparations with extended clinical effects 
and reduced dosing frequency. In order to 
develop oral drug delivery systems, it is 
necessary to optimize both the release rate of 
the drug and the residence time of the 
system within the gastrointestinal tract.  
 
Various approaches have been used to retain 
dosage forms in the stomach [1-3] in order to 
increase gastric residence time (GRT). These 
include those that utilize floating [4-7], high 
density [3], mucoadhesive [8], magnetic [9], 
unfoldable, extendible or swellable [10] and 
superporous hydrogel [11] systems. Both 
natural and synthetic polymers have been 
used to prepare floating microspheres. 
Preparation of hollow microspheres or 
microballoons of ibuprofen by the emulsion-
solvent diffusion method using acrylic 
polymers has been reported [12]. These 
systems allow prolonged residence time of 
dosage forms in the stomach and 
achievement of constant plasma levels; 
however, it is necessary to analyze 
gastrointestinal transit behavior in humans to 
confirm the suitability of the concept as far as 
final design is concerned [13]. 
 
Metformin was used as a model drug. It is an 
anti-hyperglycemic agent, which improves 
glucose tolerance in type II diabetes [14]. It is 
poorly absorbed from the lower 
gastrointestinal tract (GIT) and has a short 
elimination half life (1.5 - 1.6 h). The objective 
of the present study was to develop floating 
microballoons of metformin in order to 
achieve extended retention in the upper GIT, 
which may result in enhanced absorption and 








Metformin hydrochloride was received as a 
gift from Sohan Pharmaceuticals Ltd, Pune, 
India. Hydroxypropyl methylcellulose, ethyl 
cellulose and Tween 80 were purchased from 
Loba Chem Pvt Ltd, Mumbai, India. Ethanol 
was supplied by S.D. Fine Chem Ltd, 
Mumbai, India. Dichloromethane was 
purchased from CDH Ltd, New Delhi, India. 





Preparation of microballoons 
 
Microballoons were prepared by solvent 
evaporation technique [15]. Metformin 
hydrochloride (100 mg) and HPMC and EC 
were used in different ratios i.e. 1:1, 1:2, 1:4, 
1:6, 2:1, 4:1 & 6:1. The total weight of HPMC 
and EC per 100 mg of metformin were kept 
constant at 200 mg.  The polymers were 
dissolved in a mixture of alcohol and 
dichloromethane (in varying ratios, i.e., 1:1, 
2:1, 1:2). The total amount of solvent mixture 
was kept constant at 100 ml and the 
procedure was carried out at room 
temperature. The resulting solution was 
poured into 250 ml of distilled water 
containing 0.01 %v/v Tween 80, maintained 
at different temperatures (i.e., 10, 20, 30 and 
40 0C),  and then stirred at varying agitation 
speed (250 - 1000 rpm) for 20 min to allow 
the volatile solvent to evaporate. The 
microballoons formed were filtered, washed 
with distilled water and dried. 
 
Size and shape of microballoons 
 
The size of microballoons was determined 
using a light microscope (BEM-21, Besto 
Microscope, India) fitted with an ocular and 
stage micrometer. Scanning electron 
microscopy (SEM, Philips-XL-20, 
Netherlands) was performed to characterize 
the surface morphology of the formed 
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microballoons. Microballoons were mounted 
directly onto the sample stub and coated with 
gold film (200 nm) under reduced pressure 
(0.133 Pa), prior to measurement. 
 
Drug loading (DL), incorporation 
efficiency (IE), and yield 
 
In order to determine incorporation efficiency, 
microballoons (30 mg) were thoroughly 
triturated and suspended in 20 ml of alcohol, 
diluted (10 times) with 0.1M HCl (pH1.2) and 
filtered to remove shell fragments. Metformin 
hydrochloride content was analyzed 
spectrophotometrically (Shimadzu 1800, 
Japan) at 233 nm in order to determine drug 
loading (DL) using Eq 1. To calculate yield, 
the prepared microballoons were collected 
and weighed. Yield and incorporation 
efficiency (IE) were calculated as in Eqs 2 
and 3. 
DL (%) = (M1/M2)100  …..………… (1) 
where M1 is the amount of drug in the 
microballoons and M2 is the total weight of 
the recovered microballoons 
Yield (%) = (W1/W2)100  ………….…. (2) 
where W1 is the total weight of floating 
microballoons and W2 is the total weight of all 
non-volatile components 
IE (%) = (C1/C2)100  ……………… (3) 
where C1 is the actual (computed) drug 
content of the microballoons and C2 is the 
theoretical drug content. 
 
In vitro drug release 
 
A USP paddle apparatus (Lab India, Mumbai, 
India), containing 900 ml of 0.1M HCl (pH 
1.2) maintained at 37 ± 0.5 °C and with 
agitation speed set at 100 rpm ,was used to 
study the in vitro drug release of the 
microballoons [16]. Samples (5 ml) were 
withdrawn at intervals of 2 h, filtered through 
0.25 µm membrane filter (Millipore) and 
analyzed spectrophotometrically at 233 nm. 
The volume of the dissolution medium was 
replenished with the same amount of fresh 
dissolution fluid each time a sample was 
withdrawn to maintain sink conditions. 
Release kinetic analysis 
 
Different kinetic equations (zero-order, first 
order and Higuchi’s equation) were applied to 
the release data of the optimized batches to 
determine the release mechanism of the 
microballoons [17-19]. Drug released at 
specified time periods was plotted as percent 
drug release versus time curve (zero order 
kinetics). Similarly, log of % of unreleased 
drug was plotted versus time curve (first 
order kinetics) and percent of drug release 
was plotted versus square root of time 




Microballoons (0.3 g) were spread over the 
surface of 900 ml of simulated gastric fluid 
(pH 1.2) in a USP type II dissolution 
apparatus (Lab India, Mumbai, India). The 
medium was agitated by the paddle rotating 
at 75 rpm for 12 h. The floating and the 
settled portions of microballoons were 
recovered separately, dried and weighed. 
Buoyancy was calculated as the ratio of the 
mass of the microballoons that remained 





Statistical analysis was performed with the 
Graph Pad Instat 3 software (Graph Pad 
Software Inc, San Diego, CA). All the tests 
were run in triplicate (n = 3). Quantitative 
data were expressed as mean ± standard 
deviation (SD) and all the data were 
statistically analyzed by one way analysis of 
variance (ANOVA) with post-test (Dunnett 
multiple comparison test). Statistically 
significant difference between formulations 




Size and shape of microballoons 
 
The mean particle size of the formulations 
(P1 to P16) was in the range of 34.2 ± 4.65 to 
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95.7 ± 2.2 µm (Table 1). The mean particle 
size and wall thickness of microballoons 
increased with increase in the polymer 
concentration. The results shows that the 
larger the particle size, the longer the floating 
time. The results also show that at higher 
temperatures, the shell of the microballoons 
was very thin and some of them were broken 
(formulation P16) which might be due to the 
faster diffusion of alcohol in the droplets into 
aqueous phase and immediate evaporation 
of dichloromethane following its introduction 
into the medium. Scanning electron 
microscopy (SEM) revealed pores on the 
microballoons (Fig 1). 
 
Yield and drug loading (DL) 
 
The yield of microballoons was > 72 % for all 
the formulations while drug loading was in the 
range of 105.4 ± 1.5 to 125.5 ± 1.6 µg/mg 
(Table 1). 
 
Table 1: Effect of various processing parameters on the particle size, drug loading, incorporation efficiency 
(IE), yield and buoyancy of microballoons 
 



















    
P1 1:1 1:1 300C 54.2±2.7 74.2±1.8 116.0±1.2 78.2±1.1 73.6±2.0 
P2 1:2 1:1 300C 73.8±3.1 76.3±1.9 118.7±1.6 82.3±1.1 74.3±2.0 
P3 1:4 1:1 300C 88.2±4.0 78.2±1.6 117.6±1.8 83.6±0.8 76.6±2.2 
P4 1:6 1:1 300C 95.7±2.1 76.1±1.3 121.1±1.5 83.9±0.9 78.1±1.9 
P5 2:1 1:1 300C 34.1±4.7 75.2±1.3 113.5±1.9 77.6±0.6 73.8±2.3 
P6 4:1 1:1 300C 58.8±4.0 73.6±1.7 115.3±1.2 77.2±1.2 78.6±2.8 
P7 6:1 1:1 300C 73.6±4.0 72.5±1.7 125.5±1.6 82.7±1.0 81.4±2.0 
P9 1:2 1:1 400C 71.0±3.8 76.3±1.1 114.0±1.5 79.1±1.6 76.3±1.8 
P10 1:2 1:1 100C 56.1±2.6 72.3±1.9 114.9±1.4 75.6±1.3 74.2±2.1 
P11 1:2 1:1 200C 73.8±3.1 76.3±1.9 118.7±1.8 82.3±1.1 74.3±2.0 
P12 1:2 2:1 300C 67.4±3.1 78.6±1.5 105.4±1.5 75.3±0.9 71.2±2.3 
P13 1:2 1:1 400C 78.7±3.6 76.9±1.5 111.9±1.7 78.2±0.7 72.8±3.1 
P15 1:2 1:2 300C 71.9±3.4 78.4±1.9 110.4±1.8 78.6±1.0 74.3±1.7 
P16 1:2 1:2 200C 62.0±3.8 74.2±1.0 108.6±1.2 73.2±1.0 76.2±2.1 
* Formulations were prepared at varying agitation speed (250, 500, 750 and 1000 rpm) 
† Formulations were prepared at varying temperatures i.e. 100C, 200C, 300C & 400C 
‡ Polymer ratio (HPMC: EC) i.e. 1:1, 1:2, 1:4, 1:6, 2:1, 4:1 & 6:1.  
 
Table 2: Release kinetic data for metformin hydrochloride microballoons 
 
Formulation  Zero order* First order* Higuchi * 
Code K0 r2 K1 r2 KH r2 
P-2# 0.1215 0.909 10.517 0.983 0.0347 0.909 
P-3# 0.1597 0.921 23.008 0.954 0.0447 0.966 
P-9# 0.1242 0.900 11.517 0.983 0.0357 0.991 
P-12# 0.1211 0.883 10.312 0.964 0.0351 0.981 
P-15# 0.1215 0.909 10.5173 0.981 0.0347 0.993 
* K0 (h-1), K1 (h-1) and KH (h-1/2) are release rate constants for Zero, First and Higuchi 
   kinetic treatment respectively. 
#P-2: Polymer ratio (HPMC:EC) 1:2, Solvent ratio (E:DCM): 1:1, Temperature: 300C & Agitation speed: 250 rpm 
#P-3: Polymer ratio (HPMC:EC): 1:4, Solvent ratio (E:DCM): 1:1, Temperature: 300C & Agitation speed: 250 rpm 
#P-9: Polymer ratio (HPMC:EC): 1:2, Solvent ratio (E:DCM): 1:1, Temperature: 400C & Agitation speed: 500 rpm 
#P-12: Polymer ratio: (HPMC:EC) 1:2, Solvent ratio (E:DCM): 2:1, Temperature: 300C & Agitation speed: 750 rpm 
#P-15: Polymer ratio: (HPMC:EC) 1:2, Solvent ratio (E:DCM): 2:1, Temperature: 300C & Agitation speed: 1000 rpm 
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Figure 1: Scanning electron micrograph (SEM) of microballoons: (A) outer surface; (B) inner surface of a 
cross-section 
 
Incorporation efficiency (IE)  
 
Incorporation efficiency was in the range of 
73.2 ± 1.0 to 83.9 ± 0.9  while more than 71 
% microballoons remained floating at the end 
of 12 h. (Table 1). 
 
In vitro drug release 
 
The results in Fig. 2 indicate that the 
proportion of polymers in the formulation was 
the key factor governing drug release from 
the microballoons. As the polymer 
concentration increased, drug release from 
the microballoons decrease.  The formulation 
containing a higher proportion of EC in the 
polymer blend exhibited lower drug release 
than those with HPMC in a higher proportion. 
Another process variable that influenced drug 
release was agitation speed. At higher 
agitation speed during preparation, smaller 
microballoons were formed, resulting in 
higher drug release. Solvent composition did 
not produce a significant effect (p < 0.05) on 
drug release. Microballoons prepared at 
higher temperature (40 0C) were slightly 
larger in size due to the thin shell of the 
microballoons (Fig 3). Cumulative drug 
release by the microballoons after 12 h was  




































Figure 2: Release   profile   of   metformin    
hydrochloride    from    microballoons    containing  
(A) 
(B) 
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(A) Varying concentrations of EC (◊, P1; ■, P2; Δ, 
P3; x, P4) and (B) Varying concentrations of 






































Figure 3: Release profile of metformin 
hydrochloride from microballoons (A) prepared at 
different agitation speeds (◊, P9; ■, P10) and 
prepared with varying solvent compositions (Δ, 
P11, x, P12; O, P13); and (B) prepared at different 
temperatures (◊, P15; ■, P16)   
 
in the range of 60.5 ± 1.2 to 96.4 ± 1.1 %. 
The effects of both solvent composition and 
temperature on in vitro release of metformin 
hydrochloride were insignificant (p < 0.05). 
The release kinetic data obtained fitted most 
to the Higuchi model (Table 2), thus 
indicating that diffusion was the predominant 
mechanism of drug release. Up to 80 % of 
the microballoons remained floating for 
longer than 12 h, thereby ensuring the 
release of the drug into the simulated gastric 





Ethanol, is a good solvent for EC and HPMC 
and therefore would preferentially diffuse out 
of disperse droplets (organic phase) into the 
aqueous phase used in this study; this 
resulted in the polymer blend instantly 
solidifying as a thin film at the interface 
between the aqueous and the organic 
phases. The yield of microballoons is a 
function of diffusion of solvents in the organic 
phase into aqueous phase. It has been 
reported that when the diffusion rate of 
solvent out of emulsion droplet is too slow, 
microspheres coalesce together. Conversely, 
when the diffusion of solvent is too fast, the 
solvent may diffuse into the aqueous phase 
before stable emulsion droplets are 
developed, causing aggregation of embryonic 
microsphere droplets [20]. The results of this 
study indicate that the formation of 
microballoons is a function of process 
variables such as polymer concentration, 
solvent composition, rate of agitation and 
temperature. The temperature of the 
dispersing medium was an important factor in 
the formation of microballoons because it 
controlled the rate of evaporation of the 
solvent. The optimum temperature for the 
formation of microballoons with good floating 
properties was room temperature 
(formulation P15). 
 
The mean particle size and wall thickness of 
the microballoons increased with increase in 
polymer concentration. This may be 
attributed to increased viscosity of the 
medium at higher polymer concentration 
resulting in enhanced interfacial tension. 
Shearing efficiency diminishes also at higher 
viscosities, resulting in the formation of larger 
particles. 
 
 When the rotation speed of propeller was 
fast (1000 rpm), the average particle size 
decreased and their morphological 
(A) 
(B) 
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characteristics were maintained. At low 
rotation speed (250 rpm), the shear force was 
not sufficient to form stable emulsion 
droplets, and hence larger droplets were 
formed which subsequently aggregated. 
Thus, the optimum rotation speed for the 
formulations made in this study is medium, 
i.e., 500 rpm, based on the mean particle size 
and incorporation efficiency of formulation 
P9.  
 
Solvent composition was found to be a vital 
factor in the formulation process governing 
the yield and particle size of microballoons. 
As the amount of dichloromethane increased, 
the average particle size of microballoons 
also increased. Since alcohol preferentially 
diffused out of the emulsion droplets, 
dichloromethane became the major 
constituent of the internal organic phase. The 
polymer, not being soluble at the interface 
between dichloromethane and aqueous 
phase, progressively solidified around 
dichloromethane-rich emulsion droplets and 
the volume of dichloromethane within the 
droplets became the size determining factor. 
The content of dichloromethane also affected 
the morphology of microballoons and the best 
results were obtained at alcohol : 
dichloromethane ratio of 2:1 (formulation 
P12). 
 
Microballoons formulated with the polymer 
blend in which HPMC constituted the higher 
proportion (formulations P5, P6 and P7) were 
smaller in size than microballoons in which 
EC formed the higher proportion. The solvent 
diffusion and evaporation method used 
produced spherical microballoons with 
smooth outer surface and hollow core. 
Incorporation efficiency of formulated 
microballoons was a function of process 
variables as well as the physicochemical 
properties of drug. It was observed that 
variation in polymer concentration influenced 
incorporation efficiency. This is because the 
increase in viscosity at higher polymer 
concentrations restricted the movement of 
drug from the polymer matrix into the 
aqueous phase. Drug solubility in the organic 
solvents also affected incorporation 
efficiency. The drug is hydrophilic, and 
therefore, it would leach optimally into the 
aqueous phase. However, increase in 
polymer concentration had no impact on the 
yield of microballoons.  
 
In the present study, the  polymer content of 
the formulation was the key factor governing 
drug release from the microballoons. It 
seems that as the polymer content increased, 
there was an increased in the diffusional path 
length of the drug, thus decreasing the 
overall drug release rate from the polymer 
matrix.. Also, since higher rotation speed 
yielded smaller microballoons in which in turn 
increased drug release, it is clear why higher 
agitation resulted in microballoons with faster 
drug release. The effects of both solvent 
composition and temperature on in vitro 
release of metformin hydrochloride were, 
however, insignificant (p < 0.05). The release 
kinetic data obtained fitted most to the 
Higuchi model, thus indicating that diffusion 
was the predominant mechanism of drug 
release. As high as > 80 % of the 
microballoons remained floating for longer 
than 12 h, thereby ensuring the release of the 
drug into the simulated gastric fluid in a 




Metformin hydrochloride microballoons with 
good floatation sustained release 
characteristics in simulated gastric fluid in 
vitro has been successfully developed using 
the solvent evaporation and diffusion method. 
In vivo studies are, however, required to 
establish the suitability of the formulation 




The authors are very grateful to College of 
Pharmacy, IPS Academy, Indore, for 
providing all the necessary facilities for 
carrying out this study. The authors also wish 
to thank Dr Praveen Malviya, Indian Institute 
Yadav & Jain 
Trop J Pharm Res, August 2012;11 (4): 568 
of Technology (IIT), New Delhi, India, for 





1. Moes AJ. Gastroretentive dosage forms. Crit. Rev. 
Ther. Drug. Syst. 1993; 10: 143-195. 
2. Deshpande AA, Rhodes CT, Shah NH, Malick AW. 
Controlled release drug delivery systems for 
prolonged gastric residence: an overview. 
Drug Dev. Ind. Pharm. 1996; 22: 531-539. 
3. Hwang SJ, Park H, Park K. Gastric retentive drug 
delivery systems. Crit. Rev. Ther. Drug Carr. 
Syst. 1998; 15: 243-284. 
4. Yuasa H, Takashima Y, Kanaya Y. Studies on the 
development of intragastric floating and 
sustained release preparation: I. Application of 
calcium silicate as a floating carrier. Chem. 
Pharm. Bull. 1996; 44: 1361-1366. 
5. Rouge N, Cale ET, Doelker E, Buri P. Buoyancy and 
drug release patterns of floating minitablets 
containing piretanide and atenolol as model 
drugs. Pharm. Dev. Technol. 1998; 3: 73-84. 
6. Lee JH, Park TG, Choi HK. Development of oral drug 
delivery system using floating microspheres. J. 
Microencapsul. 1999; 16: 715-729. 
7. Tripathi G, Singh S. Formulation and In vitro 
evaluation of pH sensitive oil entrapped 
polymeric blended gellan gum buoyant beads 
of clarithromycin, DARU. 2010; 18: 247-253. 
8. Akiyama Y, Nagahara N, Kashihara T, Hirai S, 
Toguchi H. In vitro and in vivo evaluation of 
mucoadhesive microspheres prepared for the 
gastrointestinal tract using polyglycerol esters 
of fatty acids and a poly (acrylic acid) 
derivative. Pharm. Res. 1995; 12: 397-405. 
9. Groning R, Berntgen M, Georgarakis M. Acyclovir 
serum concentrations following peroral 
administration of magnetic depot tablets and 
the influence of extracorporeal magnets to 
control gastrointestinal transit. Eur. J. Pharm. 
Biopharm. 1998; 46: 285-291. 
10. Fix JA, Cargill R, Engle K. Controlled gastric 
emptying: Part 3. Gastric residence time of a 
nondisintegrating geometric shape in human 
volunteers. Pharm. Res. 1993; 10: 1087-1089. 
11. Park K. Enzyme-digestible swelling hydrogels as 
platforms for long-term oral drug delivery: 
synthesis and characterization. Biomaterials 
1988; 9: 435-441. 
12. Kawashima Y, Niwa T, Takeuchi H, Hino T, Itoh Y. 
Hollow microspheres for use as a floating 
controlled drug delivery system in the 
stomach. J. Pharm. Sci. 1992; 81: 135-140. 
13. Whitehead L, Fella JT, Colletta JH, Sharma HL, 
Smith AM. Floating dosage forms: an in vivo 
study demonstrating prolonged gastric 
retention. J. Control Release 1998; 55: 3-12. 
14. Yadav A, Jain DK. In-vitro characterization of 
gastroretentive microballoons prepared by the 
emulsion solvent diffusion method. J. Adv. 
Phar. Tech. Res. 2010; 1: 56-67. 
15. Streubel A, Siepmann J, Bodmeier R. Multiple unit 
gastroretentive drug delivery systems: a new 
preparation method for low density 
microparticles. J. Microencapsul. 2003; 20: 
329-347. 
16. The Indian Pharmacopoeia 2007, Vol-II, Indian 
Pharmacopoeia Commission, Ghaziabad, pp 
740-742. 
17.  Costa P, Lobo JMS. Modeling and comparison of 
dissolution profiles. Eur. J. Pharm. Sci. 2001; 
13: 123-133. 
18. Wagner JG. Interpretation of percent dissolved-time 
plots derived from testing of conventional 
tablets and capsules. J. Pharm. Sci. 1969; 58: 
1253-1257. 
19.  Schefter E, Higuchi T. Dissolution behavior of 
crystalline solvated and non-solvated forms of 
some pharmaceuticals. J. Pharm. Sci. 1963;  
52: 781-791.  
20. Kawashima Y, Iwamoto T, Niwa T, Takeuchi H, Hino 
T. Role of the solvent diffusion rate modifier in 
a new emulsion solvent diffusion method for 
preparation of ketoprofen microspheres. J. 
Microencapsul. 1993; 10: 329-340. 
 
